Boston Scientific–Penumbra Deal: Terms, Structure, and What to Track

Boston Scientific–Penumbra acquisition terms are now public, and the details help explain why Penumbra, Inc. (PEN) moved sharply pre-market and why Boston Scientific Corporation (BSX) traded differently. This post breaks down what the agreement says (based on the companies’ Form 8-K disclosures) and gives you a clean checklist for what to watch from here.

What happened (in plain English)

Boston Scientific and Penumbra announced a definitive agreement for Boston Scientific to acquire Penumbra in a transaction that mixes cash and Boston Scientific stock.

The headline numbers being discussed in the market are grounded in the companies’ disclosures: Penumbra is valued at $374 per share, with an enterprise value cited as approximately $14.5 billion.

The deal structure: cash election vs stock election (and why it matters)

The merger is structured with elections, but it is not “choose any mix you want without constraints.”

For each Penumbra share, holders can elect one of the following (subject to proration mechanics described below):

• Stock election: 3.8721 Boston Scientific shares per Penumbra share
• Cash election: $374.00 in cash per Penumbra share
• No valid election: consideration is determined under the merger agreement mechanics

Proration is a big part of the structure:

• The total Penumbra shares receiving cash consideration is set to 73.26% of eligible shares (excluding certain categories like canceled and dissenting shares).
• The total Penumbra shares receiving stock consideration is set to 26.74% of eligible shares.

Practical implication for investors: even if you elect all-cash (or all-stock), you may not receive 100% in that form because the election results are pushed back toward the fixed cash/stock mix.

Who is buying whom (and the legal vehicle)

The structure disclosed is a classic merger-sub acquisition:

• Boston Scientific is the “Parent.”
• A wholly owned subsidiary, Pinehurst Merger Sub, Inc., merges into Penumbra.
• Penumbra survives as a wholly owned subsidiary of Boston Scientific.

Key closing conditions investors should track

The disclosures outline several standard but important closing gates, including:

• Stockholder approval: Penumbra shareholder approval is required.
• Regulatory approvals: antitrust clearance, including expiration/termination of Hart-Scott-Rodino waiting periods and other jurisdictions’ antitrust approvals as applicable.
• S-4 registration statement effectiveness: because part of the consideration is Boston Scientific stock, the stock issuance is expected to be registered via a Form S-4.
• NYSE listing approval: for the Boston Scientific shares to be issued as stock consideration.
• No financing condition: the transaction is not subject to a financing condition (important when assessing closing risk).

Deal-protection terms: termination fees (read these carefully)

Termination fees can shape negotiating leverage, interloper risk, and the downside scenario if the deal breaks.

As disclosed:

• Penumbra termination fee payable to Boston Scientific: $525,000,000 under specified circumstances (including a superior proposal path or a board recommendation change scenario described in the filing).
• Boston Scientific termination fee payable to Penumbra: $900,000,000 under certain antitrust-related failure scenarios, with conditions (including Penumbra stockholder approval having been obtained and other conditions satisfied, among other requirements in the disclosure).

Interpretation: when the reverse termination fee is higher, it often signals the parties are explicitly allocating regulatory risk to the buyer more heavily than usual, but you still need to read the exact triggers and conditions rather than assuming it is “automatic.”

What happens to PEN shares if the deal closes

If the merger closes, Penumbra expects:

• Delisting from NYSE
• Deregistration under the Exchange Act as promptly as practicable after the effective time

That matters for anyone thinking about the post-close life of the ticker and what continuing disclosures will look like.

What this agreement does not tell you yet (but future filings will)

The initial 8-K disclosure gives you structure and major conditions, but several investor-critical items typically require follow-on filings:

• Full merger agreement exhibits (often filed with redactions and schedules omitted)
• The combined proxy statement/prospectus (commonly through the Form S-4 process)
• Detailed synergies, integration plans, and risk factors in the proxy/prospectus
• Timelines and regulatory correspondence as the process advances

For a repeatable diligence checklist on merger filings and S-4 analysis, see How to Read S-4 Merger Deals: Synergies, Dilution, Fees.

Investor checklist: questions to answer before you underwrite the spread

Use this as a quick decision framework (not financial advice, just analysis hygiene):

• Consideration math: What is the implied value of the stock election at today’s BSX price, and how does it compare to the cash election?
• Proration exposure: If you want all-cash (or all-stock), how could proration change your realized mix?
• Regulatory path: Which antitrust regimes are likely to matter most, and what is the realistic clearance timeline?
• Break risk: If the deal fails, what is your view of standalone PEN valuation vs where the stock would trade?
• Timing risk: How long could your capital be tied up while you wait for shareholder vote, S-4 effectiveness, and regulatory approvals?

How to monitor the deal inside Alpha Analyst (repeatable workflow)

Alpha Analyst is well-suited for M&A monitoring because it combines filing search, watchlists, and dashboards in one research loop.

Step 1: Put BSX and PEN on a dedicated watchlist

Create a watchlist for the transaction (or add both names to an existing “M&A / Event” list). This gives you one-click filtering across Search, Dashboards, and monitoring widgets.

Step 2: Track the filings that actually move the timeline

In Search, focus on:

• 8-Ks for ongoing deal updates
• Registration statements/prospectus materials related to the stock component (e.g., Form S-4 and subsequent amendments, when filed)
• Proxy materials tied to the required Penumbra shareholder vote

Then save the search so it becomes a living monitor rather than a one-time lookup.

Step 3: Build a “deal desk” dashboard

Create a dashboard with widgets such as:

• Recent Filings (filtered to your BSX/PEN watchlist)
• Keyword Search widget for terms like “Merger Agreement,” “S-4,” “antitrust,” “termination fee,” “go-shop,” “superior proposal,” and “Hart-Scott-Rodino”
• Side-by-side recent filing views so you can compare buyer vs target disclosures quickly

Step 4: Use AI Chat to turn dense filings into a structured brief

After the next wave of filings arrives (especially the proxy/prospectus), use AI Chat to extract:

• Consideration and proration mechanics
• Closing conditions and outside dates (if disclosed later)
• Termination triggers and fee conditions
• Any disclosed remedies, covenants, or regulatory commitments

Keep the conversation bookmarked so your “deal notes” stay updated as new documents appear.

Step 5: Annotate the clauses you’ll reuse in every update

When you find high-leverage passages (proration, termination fees, covenants, regulatory conditions), highlight and annotate them. Later, you can filter your annotations by company/watchlist and quickly rebuild a refreshed deal summary without re-reading the entire document set.

What to watch next (near-term catalysts)

Expect the next meaningful information to come through:

• Additional current reports as the process advances
• The registration/proxy workflow associated with the stock portion of the deal
• Any regulatory updates (especially if timing shifts)